By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Mesoblast Limited 

Level 1, 843A Glenhuntly Road

Caulfield South  VIC  3162  Australia
Phone: 03-9618-7000 Fax:



Company News
Mesoblast (MSB.AX) Plans to Reduce FY17 Cash Burn to Fund Clinical Operations and Phase III Heart Failure Trial 7/1/2016 9:17:18 AM
Mesoblast (MSB.AX) Stock Sinks 42% After Teva (TEVA) Withdraws from Heart Failure Trials 6/14/2016 6:42:01 AM
Mesoblast (MSB.AX) Provides Strategic Update And Reports On First Quarter Financial Results 12/17/2015 8:03:54 AM
Mesoblast (MSB.AX)’s Japan Licensee Receives Pricing For TEMCELL HS Inj. For Treatment Of Acute Graft Versus Host Disease 11/30/2015 7:19:20 AM
Mesoblast (MSB.AX) Lists On Nasdaq 11/16/2015 7:58:00 AM
Mesoblast (MSB.AX) Announces Pricing Of Public Offering On Nasdaq 11/13/2015 7:22:41 AM
Mesoblast (MSB.AX) Release: Key United States Patent Granted For The Treatment Of Heart Diseases, Stroke And Other Vascular Conditions 10/28/2015 7:21:02 AM
Mesoblast (MSB.AX) Chairman's Address To 2015 Annual General Meeting 10/22/2015 8:31:37 AM
Celgene (CELG) And Mesoblast (MSB.AX) Extend Agreement 10/16/2015 7:48:56 AM
Phase II Trial Results Show Mesoblast (MSB.AX) Cell Therapy Has Greatest Cardioprotective Effect In Patients With Advanced Heart Failure 9/30/2015 7:11:47 AM